OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
1.385
-0.015 (-1.07%)
Apr 29, 2026, 12:17 PM EDT - Market open
OmniAb Revenue
In the year 2025, OmniAb had annual revenue of $18.67M, down -29.27%. OmniAb had revenue of $8.38M in the quarter ending December 31, 2025, a decrease of -22.47%.
Revenue (ttm)
$18.67M
Revenue Growth
-29.27%
P/S Ratio
10.86
Revenue / Employee
$209,730
Employees
89
Market Cap
200.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.67M | -7.73M | -29.27% |
| Dec 31, 2024 | 26.39M | -7.77M | -22.75% |
| Dec 31, 2023 | 34.16M | -24.91M | -42.17% |
| Dec 31, 2022 | 59.08M | 24.33M | 70.02% |
| Dec 31, 2021 | 34.75M | 11.48M | 49.34% |
| Dec 31, 2020 | 23.27M | 4.95M | 27.02% |
| Dec 31, 2019 | 18.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| MacroGenics | 149.50M |
| Voyager Therapeutics | 40.37M |
| MediWound | 16.96M |
| Caribou Biosciences | 11.16M |
OABI News
- 5 days ago - OmniAb to Participate in Three Upcoming Investor Conferences - Business Wire
- 8 days ago - OmniAb to Report First Quarter 2026 Financial Results on May 7 - Business Wire
- 7 weeks ago - OmniAb Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - OmniAb to Participate at the Leerink Partners Global Healthcare Conference - Business Wire
- 2 months ago - OmniAb to Report Fourth Quarter 2025 Financial Results on March 4 - Business Wire
- 4 months ago - OmniAb Transcript: Investor Update - Transcripts
- 4 months ago - Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies - Business Wire